SHANGHAI, China – September 26, 2025 – MediumBank (Shanghai MediumBank Biotechnology Co., Ltd.) recently concluded its active participation in two premier industry events this September: Bioprocess International (BPI) Conference 2025 in Boston, USA (September 16-18) and BIONNOVA Beijing Innovation Summit 2025 in Beijing, China (September 23-24). This dual-continent engagement highlighted MediumBank's innovative capabilities and global perspective in cell culture media and integrated bioprocess solutions.
As one of the most authoritative events in biomanufacturing, BPI 2025 served as a key gathering point for industry and academia to exchange new technologies and methodologies. The conference agenda comprehensively covered upstream and downstream processing, analytical development, manufacturing strategies, and cell & gene therapy.
Boston · BPI 2025 Recap
Throughout the three-day conference, the MediumBank team engaged with clients and partners from North America, Europe, and Asia. Discussions centered on critical topics such as bioprocess optimization for enhanced productivity, cost reduction, and current market dynamics. Several preliminary collaboration agreements were established with leading CDMOs and biopharmaceutical companies.
Demonstrating its proactive global strategy and robust overseas supply chain, MediumBank showcased its portfolio—including CHO cell basal and feed media, as well as HEK293 transient transfection media—which is already successfully supplied to customers across North America, Europe, and Asia.
Beijing · BIONNOVA 2025 Recap
The 4th BIONNOVA Beijing Innovation Forum focused on translating technology into commercial success, presenting innovations and trends across the entire biopharmaceutical industry chain.
At this event, MediumBank emphasized its commitment to the domestic market, presenting its comprehensive media development platform and tailored solutions for key areas such as antibodies, ADCs, and cell & gene therapy (CGT). The booth attracted significant attention from innovative domestic biotech firms and CDMO partners.
Engagements at BIONNOVA focused on pressing industry needs, including domestic substitution, supply chain security, and process optimization for cost control, reinforcing MediumBank's role as a key partner within China's biopharmaceutical supply ecosystem.
Although held on different continents, both events shared a unified theme: "Making Bioprocessing Simpler and More Efficient."
Through these two high-profile forums, MediumBank not only demonstrated its technical expertise to the global market but also gained precise insights into regional demands. The company remains committed to empowering the global biopharmaceutical value chain with high-quality media products and professional bioprocess services, accelerating the development and commercialization of innovative therapeutics.
MediumBank extends its sincere gratitude to all partners, clients, and friends who visited our booths and supported us. We look forward to collaborating to shape a promising future for biopharmaceuticals.